Apoptosis

Apoptosis is an autonomous, genetically controlled, orderly death of cells to maintain the stability of the internal environment. Unlike necrosis, apoptosis is not a passive process, but an active one, involving the activation, expression and regulation of a series of genes, and it is not a phenomenon of autologous damage under pathological conditions, but an active death process for better adaptation to the survival environment. Apoptosis is a fundamental biological phenomenon of cells and plays a necessary role in the removal of unwanted or abnormal cells in multicellular organisms. It plays an important role in the evolution of organisms, the stability of the internal environment, and the development of several systems. Apoptosis is not only a specific type of cell death, but also has important biological significance and complex molecular biological mechanisms.

Cat. No.	Product name
BP10861	Paederosidic acid
BP10861	Paederosidic acid has significant anti-tumor, anticonvulsant and sedative effects. Paederosidic acid increases brain gamma-aminobutyric acid and decreases glutamic acid in the brain, and it up-regulates expressions of GAD 65, may be a promising future therapeutic agent for treatment of epilepsy.
BP10215	Pamufetinib
BP10215	TAS-115 is a potent inhibitor of VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase(IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectively).
BP10042	Pantoprazole
BP10042	Pantoprazole is a proton pump inhibitor used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease.
BP10453	Pantoprazole sodium
BP10453	Pantoprazole Sodium is the sodium salt form of a substituted benzimidazole with proton pump inhibitor activity. Pantoprazole is a lipophilic, weak base that crosses the parietal cell membrane and enters the acidic parietal cell canaliculus where it becomes protonated, producing the active metabolite sulfenamide, which forms an irreversible covalent bond with two sites of the H+/K+-ATPase enzyme located on the gastric parietal cell, thereby inhibiting both basal and stimulated gastric acid production.
BP10711	Pantoprazole Sodium Hydrate
BP10711	Pantoprazole is a proton pump inhibitor drug, used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease.
BP10948	Parthenolide
BP10948	(-)-Parthenolide, an inhibitor of the Nuclear Factor-κB Pathway, also promotes the ubiquitination of MDM2 and activates p53 cellular functions.
BP10592	PATULIN
BP10592	Patulin is a mycotoxin produced by a variety of molds commonly found in rotting apples, including Aspergillus and Penicillium.
BP10036	PCI-33380
BP10036	PCI-33380 is an irreversible inhibitor of Bruton's Tyrosine Kinase.
BP10839	PD0166285
BP10839	PD0166285 is a potent Wee1 and Chk1 inhibitor with activity at nanomolar concentrations.PD0166285 is a novel G2 checkpoint abrogator.
BP10785	PD-089828
BP10785	PD 089828 is a competitive inhibitor of the receptor tyrosine kinases FGFR1, PDGFRβ, and EGFR (IC50s = 0.15, 1.76, and 5.47 μM, respectively) and a noncompetitive inhibitor of the nonreceptor tyrosine kinase c-Src (IC50 = 0.18 μM)
BP10627	PD153035
BP10627	PD153035 hydrochloride is an effective and selective inhibitor of EGFR (Ki/IC50: 5.2/29 pM, in cell-free assays); little inhibitory against FGFR, PGDFR, InsR, CSF-1 and Src.
BP10830	PD153035 hydrochloride
BP10830	PD153035 hydrochloride (ZM 252868; AG 1517) is a effective and selective inhibitor of EGFR (Ki: 5.2 pM, IC50: 29 pM); few influence against FGFR, PGDFR, InsR, CSF-1, and Src.
BP10751	PD158780
BP10751	PD 158780 reversibly inhibits auto and transphosphorylation of all four members of the ErbB receptor superfamily: EGFR, ErbB2, ErbB3, and ErbB4 (IC50s: 8μM, 49 nM, 52 nM, and 52 nM in cell assay).
BP10880	PD-161570
BP10880	PD-161570 is a potent and ATP-competitive human FGF-1 receptor inhibitor with an IC50 of 39.9 nM and a Ki of 42 nM. PD-161570 also inhibits the PDGFR, EGFR and c-Src tyrosine kinases with IC50 values of 310 nM, 240 nM, and 44 nM, respectively.
BP10879	PD-166866
BP10879	PD166866 is a selective FGFR tyrosine kinase inhibitor.
BP10891	PD168393
BP10891	PD168393 is an irreversible EGFR inhibitor (IC50: 0.70 nM), irreversibly alkylate Cys-773; inactive against PKC, FGFR, PDGFR, and insulin.
BP10441	Pembrolizumab
BP10441	Pembrolizumab is a humanized monoclonal antibody and the first in the class of agents called the HER2 dimerization inhibitors impairs the ability of HER2 to bind to other members of the HER family.
BP10598	Pemetrexed disodium
BP10598	Pemetrexed is a parenterally administered folate antagonist and antineoplastic agent, used in the treatment of non-small cell lung cancer and malignant mesothelioma. Pemetrexed therapy has been associated with moderate rates of serum enzyme elevations during therapy, but has not been convincingly linked to instances of acute, clinically apparent liver injury.
BP10606	Pemigatinib
BP10606	Pemigatinib is an orally active, selective inhibitor of FGFR(IC50s of 0.4 nM, 0.5 nM, 1.2 nM, 30 nM for FGFR1, FGFR2, FGFR3, FGFR4, respectively).
BP10657	Perifosine
BP10657	Perifosine is an oral-active, alkyl-phosphocholine Akt inhibitor with potential antineoplastic activity.